K-V Pharmaceutical Co - FORM S-1 - EX-23.2 - CONSENT OF BDO USA - July 8, 2011

Attached files

file filename
S-1 - FORM S-1 - K-V Pharmaceutical Cods1.htm
EX-5.1 - OPINION OF THOMPSON COBURN LLP - K-V Pharmaceutical Codex51.htm
EX-99.3 - FORM OF LETTER TO CLIENTS - K-V Pharmaceutical Codex993.htm
EX-99.4 - FORM OF NOTICE OF GUARANTEED DELIVERY - K-V Pharmaceutical Codex994.htm
EX-23.3 - CONSENT OF KPMG LLP, - K-V Pharmaceutical Codex233.htm
EX-25.1 - FORM T-1 - K-V Pharmaceutical Codex251.htm
EX-99.2 - FORM OF LETTER TO BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER - K-V Pharmaceutical Codex992.htm
EX-99.1 - FORM OF LETTER OF TRANSMITTAL - K-V Pharmaceutical Codex991.htm
EX-12.1 - STATEMENT RE COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES - K-V Pharmaceutical Codex121.htm
EX-99.5 - FORM OF INSTRUCTIONS FROM BENEFICIAL OWNER - K-V Pharmaceutical Codex995.htm
EX-10.40 - ASSET PURCHASE AGREEMENT - K-V Pharmaceutical Codex1040.htm

Exhibit 23.2

Consent of Independent Registered Public Accounting Firm

The Board of Directors

K-V Pharmaceutical Company

Bridgeton, Missouri

We hereby consent to the incorporation by reference in the prospectus constituting a part of this Registration Statement of our report dated June 10, 2011 (except for the 2011 and 2010 condensed consolidating financial information as presented in Note 26, which is as of July 8, 2011), relating to the 2011 and 2010 consolidated financial statements and financial statement schedule, and of our report dated June 10, 2011 related to the effectiveness of the Company’s internal control over financial reporting, which appear in the Company’s Annual Report on Form 10-K for the year ended March 31, 2011.

Our report on the consolidated financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

Our report on the effectiveness of internal control over financial reporting expresses an adverse opinion on the effectiveness of the Company’s internal control over financial reporting as of March 31, 2011.

We also consent to the reference to us under the caption “Experts” in the prospectus.

 

/s/ BDO USA, LLP
Chicago, Illinois
July 8, 2011

K-V Pharmaceutical Co Reports

Also read